Skip to content

Patients › General-Health

Salud ósea y osteoporosis

How bone strength affects fractures, fixation and recovery — bone density, fragility fractures, and what helps keep bones strong (lifestyle, supplements and medications).

Updated Sep 2026
Sección transversal del hueso trabecular que muestra su estructura interna en forma de panal.
El hueso es un tejido vivo; su estructura interna en forma de panal se vuelve más delgada con la edad y la osteoporosis, lo que aumenta el riesgo de fracturas. Kieran Hirpara 4.0

Esta página se tradujo automáticamente y todavía no la ha revisado un médico. La versión en inglés es la versión oficial.

¿Qué es?

La osteoporosis significa que los huesos han perdido densidad; por eso son más delgados y frágiles de lo normal. Imagine el hueso sano como un panal de abejas con paredes gruesas. En la osteoporosis, esas paredes se vuelven delgadas y presentan numerosos huecos. El hueso sigue estando allí, pero se rompe con mayor facilidad; a veces basta una pequeña caída o incluso un simple golpe. Esta clase de fractura se denomina fractura por fragilidad.

Esta afección es frecuente después de la menopausia y su probabilidad aumenta con la edad. Algunas personas solo se enteran de que padecen osteoporosis tras sufrir una fractura, ya que suele haber un intervalo entre el momento en que ocurre la fractura y el diagnóstico y tratamiento correspondientes [1]. Ese intervalo es importante. Diversos ensayos han demostrado que tratar la osteoporosis tras una fractura por fragilidad puede reducir el riesgo de sufrir otra fractura hasta en un 50 %, además de disminuir la mortalidad hasta en un 30 % [2].

Mecanismo de acción: el cuerpo remodela constantemente los huesos, descomponiendo el hueso viejo y formando uno nuevo. La osteoporosis se desarrolla cuando la descomposición supera a la formación. Algunos tratamientos frenan dicha descomposición; otros, llamados tratamientos anabólicos, estimulan la formación ósea. Existe un enfoque que consiste en aplicar primero un tratamiento anabólico y luego cambiar a uno que ralentice la descomposición [3]. Es posible medir la densidad ósea, y ciertos modelos basados en marcadores de análisis de sangre rutinarios ayudan a predecir el riesgo de fractura [4].

Hay otros aspectos relevantes que vale la pena conocer. En nueve estudios, cada aumento de 1 unidad en el índice de masa corporal se asoció con una reducción del 9 % en el riesgo de osteoporosis [5]. El ejercicio también resulta beneficioso: el ejercicio de resistencia y de impacto fortalece los huesos; los ejercicios de equilibrio previenen las caídas; y los ejercicios de extensión espinal mejoran la postura [6]. Si padece osteoporosis y necesita cirugía de hombro, esto no supone un impedimento. Las tasas de complicaciones generales tras la reparación artroscópica del manguito rotador fueron bajas; por ello, la osteoporosis no debe considerarse motivo para evitar dicha intervención [7].

¿Funciona?

Sí, pero depende de lo que entienda por “funcionar”. No existe una única cura para la osteoporosis. El objetivo es fortalecer los huesos y reducir el riesgo de fracturas. Algunos tratamientos logran esto eficazmente; otros todavía se encuentran en fase de prueba.

La evidencia más sólida apoya a los medicamentos que frenan la pérdida ósea o estimulan la formación de nuevo hueso. Un estudio amplio demostró que una inyección de una hormona osteoinductora acelera la curación de fracturas: 7,8 semanas frente a 12,6 semanas sin el tratamiento [1]. Otros fármacos, llamados bifosfonatos, protegen los huesos mejor que los antiguos aerosoles nasales [2]. El ejercicio también es fundamental: el entrenamiento de resistencia y los ejercicios de impacto fortalecen los huesos; los ejercicios de equilibrio previenen caídas; y los ejercicios de extensión espinal mejoran la postura y podrían disminuir el riesgo de fractura vertebral [3].

Existen otros tratamientos con evidencia menos contundente. Algunos estudios pequeños indican que la acupuntura podría aliviar los síntomas [4]. Una cápsula herbal tradicional parece beneficiar tanto el dolor como la densidad ósea [5]. La terapia con células madre muestra resultados prometedores en estudios con animales, pero aún no está lista para uso humano [6]. Los investigadores también estudian si el momento de aplicar la inyección diaria influye en su eficacia, así como si nuevas herramientas como radiografías de mano y calculadoras en línea permiten detectar la pérdida ósea antes [7, 8, 9].

Existen ciertas carencias evidentes: muchas personas que sufren una fractura de cadera no reciben medicación ósea posteriormente, a pesar de que las guías clínicas lo recomiendan [10]. Además, no existe un método perfecto para estudiar esta enfermedad en laboratorio, por lo que aún quedan interrogantes sin resolver [11].

¿Qué significa esto para usted? Si padece osteoporosis, existen tratamientos comprobados que reducen el riesgo de nuevas fracturas. Su médico le explicará qué opciones son adecuadas para usted y le informará con sinceridad sobre aquellos tratamientos con evidencia limitada.

¿Cuáles son los riesgos?

El principal riesgo de la osteoporosis en sí es la fractura. Los huesos de la cadera, la columna vertebral y la muñeca se rompen con mayor facilidad cuando son frágiles. Si se produce una fractura y posteriormente no se trata la osteoporosis, es muy probable que se produzca otra fractura. Los estudios demuestran que muchas personas que sufren una fractura de cadera no reciben tratamiento óseo, a pesar de que las guías clínicas lo recomiendan [1]. En un estudio realizado con mujeres ingresadas en el hospital por fracturas, el 76,9 % padecía osteoporosis [2]. En dicho estudio, la menopausia prolongada, las fracturas vertebrales y las fracturas recientes identificaron a las mujeres con mayor riesgo [2].

Los riesgos del tratamiento dependen del tipo de terapia empleada. Los comprimidos de bisfosfonatos son más eficaces que los antiguos aerosoles nasales para proteger el hueso; por ello, los aerosoles nasales se reservan generalmente para personas que no pueden tomar los medicamentos de primera línea [3]. Algunas opciones más recientes todavía se están investigando. Actualmente se lleva a cabo un ensayo para determinar el momento óptimo para aplicar una inyección diaria que fortalezca el hueso [4]. La acupuntura y las cápsulas a base de hierbas cuentan con cierta evidencia de eficacia, aunque ésta es menor que la que respalda los medicamentos convencionales [5, 6]. La terapia con células madre, por ahora, solo se ha probado en animales; por lo tanto, sus efectos en humanos son desconocidos [7].

Si necesita cirugía, hay algunos aspectos específicos a considerar. Las mediciones de densidad ósea realizadas antes de la operación no permiten predecir si una fractura no sanará; por eso, dicha prueba carece de valor clínico para ese fin [8]. En pacientes con huesos frágiles sometidos a prótesis articulares, las tasas de complicaciones a los 2 y 5 años fueron bajas y similares, independientemente de si tomaron o no comprimidos reductores de ácido en el período perioperatorio [9]. En procedimientos de columna en los que se inyecta cemento en una vértebra fracturada, el uso continuo de cemento junto con el tratamiento estándar contra la osteoporosis se asoció con buenos resultados [10].

Un último riesgo que merece mención: la información disponible en internet sobre la osteoporosis a menudo no cumple con los estándares básicos de calidad [11]. Verifique siempre el origen de la información y consulte sus dudas con su médico.

¿Es adecuado para usted?

Vale la pena considerar el tratamiento si le han diagnosticado osteoporosis, especialmente después de una fractura. Las mujeres posmenopáusicas son el grupo más afectado. En un estudio realizado con mujeres ingresadas en el hospital por fracturas, la mayoría padecía osteoporosis; los signos de alerta más importantes fueron una menopausia prolongada, una fractura vertebral o una fractura reciente [1]. Si alguno de estos casos se aplica a usted, es lógico preguntar sobre la salud de sus huesos.

El tratamiento también podría ser adecuado si desea mantenerse activa y reducir el riesgo de caídas. Además de la medicación, las recomendaciones clave son ejercicios de resistencia e impacto para fortalecer los huesos, ejercicios de equilibrio para prevenir caídas, y ejercicios de extensión espinal para mejorar la postura [2]. Puede empezar a hablar de estos temas con su médico hoy mismo.

Probablemente el tratamiento no sea necesario si sus huesos están sanos, no tiene antecedentes de fracturas ni factores de riesgo importantes. Asimismo, si ya toma medicamentos para los huesos, esta página trata sobre si debe continuar con ellos, no sobre si debe empezar a tomarlos.

En comparación con no hacer nada, el tratamiento es la opción más recomendable tras una fractura. Entre los distintos tratamientos disponibles, cada uno actúa de forma diferente: algunos ralentizan la pérdida ósea, otros favorecen la formación de nuevo hueso, y algunos hacen ambas cosas de forma secuencial [3]. Su médico podrá explicarle cuál se adapta mejor a usted.

Esta debe ser una decisión conjunta. Lleve consigo sus preguntas, su historial de fracturas y la lista de medicamentos que toma. Pregunte qué indica su densidad ósea y qué significa para usted. La respuesta correcta depende de sus huesos, su salud y sus objetivos, no de un único resultado de prueba.

Conclusión

Si le han diagnosticado osteoporosis o si se ha fracturado un hueso tras una simple caída, merece la pena tomar medidas. Tratar la fragilidad ósea después de una fractura reduce la probabilidad de sufrir otra fractura, y también puede disminuir el riesgo de muerte prematura [1]. Lo que se puede esperar realistamente es tener huesos más fuertes y menos fracturas, no una curación total. La advertencia más importante: a muchas personas que se fracturan la cadera nunca se les prescribe medicación para los huesos posteriormente, por lo que quizás deba usted mismo plantear el tema [2].

Referencias

[1] La brecha en el tratamiento de la osteoporosis en Canadá. BMC Musculoskeletal Disorders. 2004. DOI: 10.1186/1471-2474-5-11

[2] Tratamiento médico de la osteoporosis y el papel del médico. Injury. 2016. DOI: 10.1016/s0020-1383(16)30014-6

[3] Eficacia de los agentes anabólicos y antirresortivos para prevenir fracturas por osteoporosis posmenopáusica: revisión sistemática y metanálisis de red. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06040-3

[4] Enfoque SuperLearner para predecir el riesgo inminente de fractura en pacientes chinos mayores con diagnóstico reciente de osteoporosis, basado en marcadores de análisis de sangre rutinarios. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09768-z

[5] Asociación entre el índice de masa corporal y la osteoporosis, considerando las diferencias de género: revisión sistemática y metanálisis dosis-respuesta. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09675-3

[6] Fuerte, estable y recto: declaración de consenso del Reino Unido sobre actividad física y ejercicio en la osteoporosis. British Journal of Sports Medicine. 2022. DOI: 10.1136/bjsports-2021-104634

[7] La osteoporosis es un factor de riesgo para complicaciones y reoperaciones a 1 y 3 años tras la reparación artroscópica del manguito rotador. JSES International. 2026. DOI: 10.1016/j.jseint.2026.101678

[8] Uso de teriparatida en pacientes con fracturas osteoporóticas. Injury. 2016. DOI: 10.1016/s0020-1383(16)30009-2

[9] Revisión del calcitonín salmón intranasal: evidencia histórica sobre la osteoporosis y su posible rol en el manejo del dolor ortopédico agudo. JBJS Reviews. 2026. DOI: 10.2106/jbjs.rvw.26.00021

[10] Eficacia de la acupuntura para la osteoporosis primaria: revisión sistemática y metanálisis de ensayos controlados aleatorizados. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05513-9

[11] Efecto de las cápsulas Jintiange sobre el dolor en pacientes con osteoporosis primaria: revisión sistemática y metanálisis. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-08694-w

[12] Células madre modificadas genéticamente para la osteoporosis: revisión sistemática y metanálisis de estudios preclínicos. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-08507-0

[13] Aplicación del aprendizaje automático en el cribado de osteoporosis y osteopenia mediante radiografías de mano. The Journal of Hand Surgery. 2025. DOI: 10.1016/j.jhsa.2024.09.008

[14] Nomograma con calculadora dinámica en línea para predecir la osteoporosis: desarrollo y validación basados en NHANES. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09920-9

[15] Optimización del momento de administración de teriparatida en la osteoporosis posmenopáusica: ensayo controlado aleatorizado. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06083-6

[16] ¿Una oportunidad perdida? Tratamiento de la osteoporosis tras fracturas de cuello femoral: reducción del riesgo de fracturas de cadera secundarias. The Journal of Arthroplasty. 2026. DOI: 10.1016/j.arth.2025.07.028

[17] ¿Podemos inducir osteoporosis en animales de forma comparable a la situación humana?. Injury. 2016. DOI: 10.1016/s0020-1383(16)30002-x

[18] ¿Qué prevalencia tiene la osteoporosis en un subgrupo de alto riesgo? Estudio multicéntrico en mujeres posmenopáusicas hospitalizadas por fracturas en China. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09517-2

[19] A89 La osteoporosis no es un factor de riesgo para el desarrollo de no unión ósea: estudio de casos y controles anidado. Injury. 2011. DOI: 10.1016/s0020-1383(11)70106-1

[20] Efectos del uso perioperatorio de inhibidores de la bomba de protones en los resultados de pacientes con osteoporosis y osteopenia sometidos a artroplastia total. The Journal of Arthroplasty. 2026. DOI: 10.1016/j.arth.2025.07.067

[21] La continuidad y el volumen de cemento óseo, así como el tratamiento antiosteoporótico, garantizan buenos resultados clínicos en la vertebroplastia percutánea: estudio multicéntrico. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-024-08153-y

[22] Evaluación de la calidad de la información sobre la osteoporosis: un análisis transversal de la información sanitaria en línea. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09711-2


Evidence & references

This is the clinical evidence summary written for health professionals. It is technical, and it lists the research this page was built from. You do not need to read it to understand your treatment or to make a decision about it.

Overview

  • A bone density-based aging model approach may facilitate and support the development of precision medicine strategies in osteoporosis prevention and management [1].
  • Investigators must select an osteoporotic fracture model that best reflects the clinical problem being studied and the underlying pathophysiology of the osteoporosis in the target patient group [2].
  • Current online health information on osteoporosis often fails to meet basic standards of evidence-based health information, highlighting the urgent need to improve quality to support informed decision-making [3].
  • Each 1-unit increase in body mass index was associated with a 9% reduction in osteoporosis risk based on a dose-response analysis of nine studies [4].
  • Sequential anabolic-to-anti-resorptive therapy may inform treatment guidelines for high-risk postmenopausal populations [5].
  • There is no perfect model for osteoporosis, but a variety of models are appropriate for answering specific questions [6].
  • There is evidence of a care gap between the occurrence of a fragility fracture and the diagnosis and treatment of osteoporosis in Canada [7].
  • A nomogram with an online dynamic calculator could facilitate the early prediction, diagnosis, and treatment of osteoporosis, contributing to the bone health of the elderly population and promoting the development of public health [10].
  • Patients with osteoporosis may experience a higher incidence of medical complications within the 90-day global period than nonosteoporotic patients following rotator cuff repair [12].
  • Overall rates of complication were low and osteoporosis should not be considered a contraindication to arthroscopic rotator cuff repair [18].

How It Works

  • A randomized controlled trial on the timing optimization of teriparatide dosing is expected to provide insights into optimizing administration timing, potentially guiding personalized dosing strategies to enhance bone formation and reduce fracture risk in osteoporosis [8].
  • The book "Radiology of Osteoporosis" summarises the thoroughly researched topic of osteoporosis in a scientific approach [9].
  • Data showed no relationship between decreased bone mineral density and 2-year clinical outcomes following arthroscopic rotator cuff repair, despite previous literature showing the negative effect of osteoporosis on rotator cuff healing [11].
  • Recent research progress on natural traditional Chinese medicine products provides a theoretical and experimental basis for the development of new drugs and the improvement of osteoporosis management [13].
  • Current evidence suggests that the efficacy of acupuncture in improving the symptoms of primary osteoporosis is encouraging for its use in clinical practice as a physical intervention [14].
  • Macrophage polarization-related genes with potential causal roles in osteoporosis identified via multi-omics Mendelian randomization are exploratory and hypothesis-generating findings that require validation in bone marrow-specific and functional studies [21].
  • The gut microbiota–metabolite–bone network may be involved in the skeletal effects of leptin, providing novel mechanistic insights and potential therapeutic strategies for osteoporosis management [22].
  • MiR-137 promotes TLR4/NF-κB pathway activity through targeting KDM4A, which inhibits osteogenic differentiation of human bone marrow mesenchymal stem cells and aggravates osteoporosis [23].
  • There is some promising experimental and clinical evidence for possible enhancement of the bone repair process via administration of systemic agents [24].
  • In humans, de novo use of bisphosphonate therapy after fracture does not appear to have a significant effect on fracture healing [25].
  • Although bone quality may be diminished in the elderly, this does not influence the occurrence of nonunion [26].

What the Evidence Shows

Risk Factors and Prediction

  • Each 1-unit increase in BMI was associated with a 9% reduction in osteoporosis risk based on a dose–response analysis of nine studies [4].
  • A nomogram with an online dynamic calculator developed based on NHANES data could facilitate the early prediction, diagnosis, and treatment of osteoporosis [10].
  • A SuperLearner approach was successfully developed and validated as a fracture risk prediction model for patients newly diagnosed with osteoporosis based on routine blood test markers [29].
  • Mendelian randomization results show varying associations between diabetes and BMD across different sites and methods, with significant associations found for T2D on femoral neck and total body BMD, and HbA1c on heel BMD [30].
  • Machine learning application to hand radiographs represents a possible step toward more accessible, cost-effective, automated diagnosis and earlier treatment of osteoporosis/osteopenia [17].

Diagnosis and Information Quality

Treatment and Management

  • Randomized controlled trials have demonstrated that treatment of osteoporosis in patients with fragility fractures can reduce the risk of subsequent fractures by up to 50% and mortality rates by up to 30% [16].
  • A randomized controlled trial on teriparatide dosing timing is expected to provide insights into optimizing administration to enhance bone formation and reduce fracture risk in osteoporosis [8].
  • Intranasal salmon calcitonin is less effective than bisphosphonates and modern anabolic agents for increasing BMD and reducing fracture risk, and its use is best reserved for patients who cannot take first-line therapies due to contraindications, intolerance, or personal preference [19].
  • The current evidence suggests that the efficacy of acupuncture in improving the symptoms of primary osteoporosis is encouraging for its use in clinical practice as a physical intervention [14].
  • Natural traditional Chinese medicine products provide a theoretical and experimental basis for the development of new drugs and the improvement of osteoporosis management [13].
  • Key recommendations for people with osteoporosis include undertaking resistance and impact exercise to maximise bone strength, activities to improve strength and balance to reduce falls, and spinal extension exercise to improve posture and potentially reduce risk of falls and vertebral fractures [20].
  • Findings from a retrospective cross-sectional study on long-term hospitalized patients with muscular dystrophy may help inform strategies for osteoporotic treatment and nutritional care in this patient population [15].

Surgical Outcomes and Complications

  • Continuous bone cement and standardized treatment for osteoporosis were guarantees of good clinical outcomes for percutaneous vertebroplasty, and injected bone cement >5.5 ml might be a guarantee [28].
  • Patients who received PTH (1–84) injections accelerated radiographic and clinical fracture healing (7.8 weeks) when compared to patients who received no treatment (12.6 weeks) [27].

Research Models

Practical Considerations

Risk Factors and Screening

  • A bone density-based aging model approach may facilitate the development of precision medicine strategies in osteoporosis prevention and management [1].
  • Each 1-unit increase in body mass index is associated with a 9% reduction in osteoporosis risk [4].
  • Machine learning application to hand radiographs represents a possible step toward more accessible, cost-effective, automated diagnosis and earlier treatment of osteoporosis and osteopenia [17].

Treatment and Management

  • Treatment of osteoporosis in patients with fragility fractures can reduce the risk of subsequent fractures by up to 50% and mortality rates by up to 30% [16].
  • Intranasal salmon calcitonin is less effective than bisphosphonates and modern anabolic agents for increasing bone mineral density and reducing fracture risk [19].
  • The use of intranasal salmon calcitonin is best reserved for patients who cannot take first-line therapies due to contraindications, intolerance, or personal preference [19].
  • Optimizing teriparatide administration timing may guide personalized dosing strategies to enhance bone formation and reduce fracture risk in osteoporosis [8].
  • People with osteoporosis should undertake resistance and impact exercise to maximise bone strength [20].
  • People with osteoporosis should undertake activities to improve strength and balance to reduce falls [20].
  • People with osteoporosis should undertake spinal extension exercise to improve posture and potentially reduce risk of falls and vertebral fractures [20].

Surgical Outcomes and Complications

  • There is no relationship between decreased bone mineral density and 2-year clinical outcomes following arthroscopic rotator cuff repair [11].
  • Patients with osteoporosis may experience a higher incidence of medical complications within the 90-day global period than nonosteoporotic patients [12].
  • Osteoporosis should not be considered a contraindication to arthroscopic rotator cuff repair [18].

Research and Information Quality

  • Current online health information on osteoporosis often fails to meet basic standards of evidence-based health information [3].

Key Evidence

  • [L3] This approach may facilitate and support the development of precision medicine strategies in osteoporosis prevention and management. [1] (10.1186/s12891-025-09298-0)
  • [L5] Investigators must select a model that best reflects the clinical problem being studied, and the underlying pathophysiology of the osteoporosis in the target patient group. [2] (10.1016/s0020-1383(16)30004-3)
  • [Paper] Current OHI on osteoporosis often fails to meet basic standards of EBHI, highlighting the urgent need to improve the quality to support informed decision-making. [3] (10.1186/s12891-026-09711-2)
  • [L1] Based on our dose–response analysis of nine studies, each 1-unit increase in BMI was associated with a 9% reduction in osteoporosis risk. [4] (10.1186/s12891-026-09675-3)
  • [L1] This sequential anabolic-to-anti-resorptive therapy may inform treatment guidelines for high-risk postmenopausal populations. [5] (10.1186/s13018-025-06040-3)
  • [Paper] However, there is no perfect model for osteoporosis, but a variety of models appropriate for answering specific questions. [6] (10.1016/s0020-1383(16)30002-x)
  • [L4] There is evidence of a care gap between the occurrence of a fragility fracture and the diagnosis and treatment of osteoporosis in Canada. [7] (10.1186/1471-2474-5-11)
  • [L2] This trial is expected to provide crucial insights into optimizing teriparatide administration timing, potentially guiding personalized dosing strategies to enhance bone formation and reduce fracture risk in osteoporosis. [8] (10.1186/s13018-025-06083-6)
  • [Paper] The book summarises the thoroughly researched topic of osteoporosis in a scientific approach. [9] (10.1016/s0020-1383(03)00201-8)
  • [L3] Ultimately, this tool could facilitate the early prediction, diagnosis, and treatment of osteoporosis, thus contributing to the bone health of the elderly population and promoting the development of public health. [10] (10.1186/s12891-026-09920-9)
  • [L3] Despite previous literature showing the negative effect of osteoporosis on rotator cuff healing, our data showed no relationship between decreased bone mineral density and 2-year clinical outcomes following RCR. [11] (10.1016/j.jse.2025.02.011)
  • [L3] In addition, patients with osteoporosis may experience a higher incidence of medical complications within the 90-day global period than nonosteoporotic patient. [12] (10.1016/j.xrrt.2026.100723)
  • [L4] This paper summarises recent research progress on natural TCM products in preventing and treating osteoporosis and provides a theoretical and experimental basis for the development of new drugs and the improvement of osteoporosis management. [13] (10.1186/s13018-025-05879-w)
  • [L1] The current evidence suggests that the efficacy of acupuncture in improving the symptoms of primary osteoporosis is encouraging for its use in clinical practice as a physical intervention. [14] (10.1186/s13018-025-05513-9)
  • [L4] These findings may help inform strategies for osteoporotic treatment and nutritional care in this patient population. [15] (10.1186/s12891-026-10045-2)
  • [Paper] Randomized controlled trials have demonstrated that treatment of osteoporosis in patients with fragility fractures can reduce the risk of subsequent fractures by up to 50% and mortality rates by up to 30%. [16] (10.1016/s0020-1383(16)30014-6)
  • [L2] The findings represent a possible step toward more accessible, cost-effective, automated diagnosis and therefore earlier treatment of osteoporosis/osteopenia. [17] (10.1016/j.jhsa.2024.09.008)
  • [L3] Overall rates of complication were low and osteoporosis should not be considered a contraindication to arthroscopic RCR. [18] (10.1016/j.jseint.2026.101678)
  • [Paper] IN-CAL is less effective than bisphosphonates and modern anabolic agents for increasing BMD and reducing fracture risk; accordingly, its use is best reserved for patients who cannot take first-line therapies due to contraindications, intolerance, or personal preference. [19] (10.2106/jbjs.rvw.26.00021)
  • [L5] Key recommendations are that people with osteoporosis should undertake (1) resistance and impact exercise to maximise bone strength; (2) activities to improve strength and balance to reduce falls; (3) spinal extension exercise to improve posture and potentially reduce risk of falls and vertebral fractures. [20] (10.1136/bjsports-2021-104634)
  • [Paper] These findings are exploratory and hypothesis-generating and require validation in bone marrow-specific and functional studies. [21] (10.1186/s13018-026-06905-1)
  • [Paper] These findings suggest that the gut microbiota–metabolite–bone network may be involved in the skeletal effects of leptin, providing novel mechanistic insights and potential therapeutic strategies for osteoporosis management. [22] (10.1186/s12891-026-09950-3)
  • [Paper] This mechanism inhibits osteogenic differentiation of human bone marrow mesenchymal stem cells and aggravates osteoporosis. [23] (10.1186/s13018-023-03918-y)
  • [Paper] There is some promising experimental and clinical evidence for possible enhancement of the bone repair process via administration of systemic agents. [24] (10.1016/s0020-1383(16)30003-1)
  • [L4] In humans, de novo use of bisphosphonate therapy after fracture does not appear to have a significant effect on fracture healing. [25] (10.1016/s0020-1383(16)30015-8)
  • [L3] Although bone quality may be diminished in the elderly, this does not influence the occurrence of nonunion. [26] (10.1016/s0020-1383(11)70106-1)
  • [Paper] Patients who received the PTH (1–84) injections accelerated radiographic and clinical fracture healing (7.8 weeks) when compared to patients who received no treatment (12.6 weeks). [27] (10.1016/s0020-1383(16)30009-2)
  • [L3] Continuous bone cement and standardized treatment for osteoporosis were guarantees of good clinical outcomes for PVP, and injected bone cement >5.5 ml might be a guarantee. [28] (10.1186/s12891-024-08153-y)
  • [L3] We successfully developed and validated a fracture risk prediction model for patients newly diagnosed with osteoporosis. [29] (10.1186/s12891-026-09768-z)
  • [Paper] The results show varying associations across different BMD sites (femoral neck, lumbar spine, heel, total body) and methods (IVW, MR-Egger, Weighted median), with some significant associations found for T2D on femoral neck and total body BMD, and HbA1c on heel BMD. [30] (10.1186/s12891-024-07430-0)

References

[1] Unveiling risk factors and predicting osteoporosis through bone density based aging model: a community-based cohort in Guangdong, China. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-025-09298-0

[2] Main differences in osteoporotic fracture models: which should I use?. Injury. 2016. DOI: 10.1016/s0020-1383(16)30004-3

[3] Mapping the quality of information on osteoporosis: a cross-sectional analysis of online health information. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09711-2

[4] The association between body mass index and osteoporosis, with consideration of sex differences: a systematic review and dose-response meta-analysis. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09675-3

[5] Effectiveness of anabolic and anti-resorptive agents for preventing postmenopausal osteoporosis fractures: a systematic review and network meta-analysis. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06040-3

[6] Can we induce osteoporosis in animals comparable to the human situation?. Injury. 2016. DOI: 10.1016/s0020-1383(16)30002-x

[7] The osteoporosis care gap in Canada. BMC Musculoskeletal Disorders. 2004. DOI: 10.1186/1471-2474-5-11

[8] Timing optimization of teriparatide dosing for postmenopausal osteoporosis: a randomized controlled trial. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-06083-6

[9] Radiology of Osteoporosis. Injury. 2004. DOI: 10.1016/s0020-1383(03)00201-8

[10] A nomogram with online dynamic calculator for predicting osteoporosis: development and validation based on NHANES. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09920-9

[11] No difference in 2-year outcomes of arthroscopic rotator cuff repair in patients with osteoporosis. Journal of Shoulder and Elbow Surgery. 2025. DOI: 10.1016/j.jse.2025.02.011

[12] Impact of osteoporosis on post-operative outcomes following rotator cuff repair. JSES Reviews, Reports, and Techniques. 2026. DOI: 10.1016/j.xrrt.2026.100723

[13] Natural traditional Chinese medicine products: emerging therapeutic targets for the treatment of osteoporosis. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05879-w

[14] Efficacy of acupuncture for primary osteoporosis: a systematic review and meta-analysis of randomized controlled trials. Journal of Orthopaedic Surgery and Research. 2025. DOI: 10.1186/s13018-025-05513-9

[15] Osteoporosis in long-term hospitalized patients with muscular dystrophy: a retrospective cross-sectional study. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-10045-2

[16] Medical management of osteoporosis and the surgeons' role. Injury. 2016. DOI: 10.1016/s0020-1383(16)30014-6

[17] Application of Machine Learning to Osteoporosis and Osteopenia Screening Using Hand Radiographs. The Journal of Hand Surgery. 2025. DOI: 10.1016/j.jhsa.2024.09.008

[18] Osteoporosis is a risk factor for complications and reoperations at 1 and 3 years after arthroscopic rotator cuff repair. JSES International. 2026. DOI: 10.1016/j.jseint.2026.101678

[19] Revisiting Intranasal Salmon Calcitonin: Historical Osteoporosis Evidence and a Potential Role in Acute Orthopaedic Pain Management. JBJS Reviews. 2026. DOI: 10.2106/jbjs.rvw.26.00021

[20] Strong, steady and straight: UK consensus statement on physical activity and exercise for osteoporosis. British Journal of Sports Medicine. 2022. DOI: 10.1136/bjsports-2021-104634

[21] Macrophage polarization-related genes with potential causal roles in osteoporosis: a multi-omics Mendelian randomization study. Journal of Orthopaedic Surgery and Research. 2026. DOI: 10.1186/s13018-026-06905-1

[22] Role and mechanism of leptin in improving osteoporosis via the “gut–bone axis”. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09950-3

[23] MiR-137 promotes TLR4/NF-κB pathway activity through targeting KDM4A, inhibits osteogenic differentiation of human bone marrow mesenchymal stem cells and aggravates osteoporosis. Journal of Orthopaedic Surgery and Research. 2023. DOI: 10.1186/s13018-023-03918-y

[24] Fracture repair: general aspects and influence of osteoporosis and anti-osteoporosis treatment. Injury. 2016. DOI: 10.1016/s0020-1383(16)30003-1

[25] How do bisphosphonates affect fracture healing?. Injury. 2016. DOI: 10.1016/s0020-1383(16)30015-8

[26] A89 Osteoporosis is not a risk factor for the development of nonunion: a cohort nested case-control study. Injury. 2011. DOI: 10.1016/s0020-1383(11)70106-1

[27] Use of teriparatide in osteoporotic fracture patients. Injury. 2016. DOI: 10.1016/s0020-1383(16)30009-2

[28] Continuity and volume of bone cement and anti osteoporosis treatment were guarantee of good clinical outcomes for percutaneous vertebroplasty: a multicenter study. BMC Musculoskeletal Disorders. 2025. DOI: 10.1186/s12891-024-08153-y

[29] SuperLearner approach for predicting imminent risk of fracture in older Chinese patients with newly diagnosed osteoporosis based on their routine blood test markers. BMC Musculoskeletal Disorders. 2026. DOI: 10.1186/s12891-026-09768-z

[30] Diabetes and osteoporosis: a two-sample mendelian randomization study. BMC Musculoskeletal Disorders. 2024. DOI: 10.1186/s12891-024-07430-0

Creative Commons BY-NC 4.0

CC Creative Commons licence
BY Attribution — you must credit the source
NC NonCommercial — not for commercial use

Attribution-NonCommercial 4.0 International


Creative Commons Corporation ("Creative Commons") is not a law firm and does not provide legal services or legal advice. Distribution of Creative Commons public licenses does not create a lawyer-client or other relationship. Creative Commons makes its licenses and related information available on an "as-is" basis. Creative Commons gives no warranties regarding its licenses, any material licensed under their terms and conditions, or any related information. Creative Commons disclaims all liability for damages resulting from their use to the fullest extent possible.

Using Creative Commons Public Licenses

Creative Commons public licenses provide a standard set of terms and conditions that creators and other rights holders may use to share original works of authorship and other material subject to copyright and certain other rights specified in the public license below. The following considerations are for informational purposes only, are not exhaustive, and do not form part of our licenses.

Considerations for licensors: Our public licenses are intended for use by those authorized to give the public permission to use material in ways otherwise restricted by copyright and certain other rights. Our licenses are irrevocable. Licensors should read and understand the terms and conditions of the license they choose before applying it. Licensors should also secure all rights necessary before applying our licenses so that the public can reuse the material as expected. Licensors should clearly mark any material not subject to the license. This includes other CC- licensed material, or material used under an exception or limitation to copyright. More considerations for licensors: wiki.creativecommons.org/Considerations_for_licensors

Considerations for the public: By using one of our public licenses, a licensor grants the public permission to use the licensed material under specified terms and conditions. If the licensor's permission is not necessary for any reason--for example, because of any applicable exception or limitation to copyright--then that use is not regulated by the license. Our licenses grant only permissions under copyright and certain other rights that a licensor has authority to grant. Use of the licensed material may still be restricted for other reasons, including because others have copyright or other rights in the material. A licensor may make special requests, such as asking that all changes be marked or described. Although not required by our licenses, you are encouraged to respect those requests where reasonable. More considerations for the public: wiki.creativecommons.org/Considerations_for_licensees


Creative Commons Attribution-NonCommercial 4.0 International Public License

By exercising the Licensed Rights (defined below), You accept and agree to be bound by the terms and conditions of this Creative Commons Attribution-NonCommercial 4.0 International Public License ("Public License"). To the extent this Public License may be interpreted as a contract, You are granted the Licensed Rights in consideration of Your acceptance of these terms and conditions, and the Licensor grants You such rights in consideration of benefits the Licensor receives from making the Licensed Material available under these terms and conditions.

Section 1 -- Definitions.

a. Adapted Material means material subject to Copyright and Similar Rights that is derived from or based upon the Licensed Material and in which the Licensed Material is translated, altered, arranged, transformed, or otherwise modified in a manner requiring permission under the Copyright and Similar Rights held by the Licensor. For purposes of this Public License, where the Licensed Material is a musical work, performance, or sound recording, Adapted Material is always produced where the Licensed Material is synched in timed relation with a moving image.

b. Adapter's License means the license You apply to Your Copyright and Similar Rights in Your contributions to Adapted Material in accordance with the terms and conditions of this Public License.

c. Copyright and Similar Rights means copyright and/or similar rights closely related to copyright including, without limitation, performance, broadcast, sound recording, and Sui Generis Database Rights, without regard to how the rights are labeled or categorized. For purposes of this Public License, the rights specified in Section 2(b)(1)-(2) are not Copyright and Similar Rights.

d. Effective Technological Measures means those measures that, in the absence of proper authority, may not be circumvented under laws fulfilling obligations under Article 11 of the WIPO Copyright Treaty adopted on December 20, 1996, and/or similar international agreements.

e. Exceptions and Limitations means fair use, fair dealing, and/or any other exception or limitation to Copyright and Similar Rights that applies to Your use of the Licensed Material.

f. Licensed Material means the artistic or literary work, database, or other material to which the Licensor applied this Public License.

g. Licensed Rights means the rights granted to You subject to the terms and conditions of this Public License, which are limited to all Copyright and Similar Rights that apply to Your use of the Licensed Material and that the Licensor has authority to license.

h. Licensor means the individual(s) or entity(ies) granting rights under this Public License.

i. NonCommercial means not primarily intended for or directed towards commercial advantage or monetary compensation. For purposes of this Public License, the exchange of the Licensed Material for other material subject to Copyright and Similar Rights by digital file-sharing or similar means is NonCommercial provided there is no payment of monetary compensation in connection with the exchange.

j. Share means to provide material to the public by any means or process that requires permission under the Licensed Rights, such as reproduction, public display, public performance, distribution, dissemination, communication, or importation, and to make material available to the public including in ways that members of the public may access the material from a place and at a time individually chosen by them.

k. Sui Generis Database Rights means rights other than copyright resulting from Directive 96/9/EC of the European Parliament and of the Council of 11 March 1996 on the legal protection of databases, as amended and/or succeeded, as well as other essentially equivalent rights anywhere in the world.

l. You means the individual or entity exercising the Licensed Rights under this Public License. Your has a corresponding meaning.

Section 2 -- Scope.

a. License grant.

1. Subject to the terms and conditions of this Public License, the Licensor hereby grants You a worldwide, royalty-free, non-sublicensable, non-exclusive, irrevocable license to exercise the Licensed Rights in the Licensed Material to:

a. reproduce and Share the Licensed Material, in whole or in part, for NonCommercial purposes only; and

b. produce, reproduce, and Share Adapted Material for NonCommercial purposes only.

2. Exceptions and Limitations. For the avoidance of doubt, where Exceptions and Limitations apply to Your use, this Public License does not apply, and You do not need to comply with its terms and conditions.

3. Term. The term of this Public License is specified in Section 6(a).

4. Media and formats; technical modifications allowed. The Licensor authorizes You to exercise the Licensed Rights in all media and formats whether now known or hereafter created, and to make technical modifications necessary to do so. The Licensor waives and/or agrees not to assert any right or authority to forbid You from making technical modifications necessary to exercise the Licensed Rights, including technical modifications necessary to circumvent Effective Technological Measures. For purposes of this Public License, simply making modifications authorized by this Section 2(a) (4) never produces Adapted Material.

5. Downstream recipients.

a. Offer from the Licensor -- Licensed Material. Every recipient of the Licensed Material automatically receives an offer from the Licensor to exercise the Licensed Rights under the terms and conditions of this Public License.

b. No downstream restrictions. You may not offer or impose any additional or different terms or conditions on, or apply any Effective Technological Measures to, the Licensed Material if doing so restricts exercise of the Licensed Rights by any recipient of the Licensed Material.

6. No endorsement. Nothing in this Public License constitutes or may be construed as permission to assert or imply that You are, or that Your use of the Licensed Material is, connected with, or sponsored, endorsed, or granted official status by, the Licensor or others designated to receive attribution as provided in Section 3(a)(1)(A)(i).

b. Other rights.

1. Moral rights, such as the right of integrity, are not licensed under this Public License, nor are publicity, privacy, and/or other similar personality rights; however, to the extent possible, the Licensor waives and/or agrees not to assert any such rights held by the Licensor to the limited extent necessary to allow You to exercise the Licensed Rights, but not otherwise.

2. Patent and trademark rights are not licensed under this Public License.

3. To the extent possible, the Licensor waives any right to collect royalties from You for the exercise of the Licensed Rights, whether directly or through a collecting society under any voluntary or waivable statutory or compulsory licensing scheme. In all other cases the Licensor expressly reserves any right to collect such royalties, including when the Licensed Material is used other than for NonCommercial purposes.

Section 3 -- License Conditions.

Your exercise of the Licensed Rights is expressly made subject to the following conditions.

a. Attribution.

1. If You Share the Licensed Material (including in modified form), You must:

a. retain the following if it is supplied by the Licensor with the Licensed Material:

i. identification of the creator(s) of the Licensed Material and any others designated to receive attribution, in any reasonable manner requested by the Licensor (including by pseudonym if designated);

ii. a copyright notice;

iii. a notice that refers to this Public License;

iv. a notice that refers to the disclaimer of warranties;

v. a URI or hyperlink to the Licensed Material to the extent reasonably practicable;

b. indicate if You modified the Licensed Material and retain an indication of any previous modifications; and

c. indicate the Licensed Material is licensed under this Public License, and include the text of, or the URI or hyperlink to, this Public License.

2. You may satisfy the conditions in Section 3(a)(1) in any reasonable manner based on the medium, means, and context in which You Share the Licensed Material. For example, it may be reasonable to satisfy the conditions by providing a URI or hyperlink to a resource that includes the required information.

3. If requested by the Licensor, You must remove any of the information required by Section 3(a)(1)(A) to the extent reasonably practicable.

4. If You Share Adapted Material You produce, the Adapter's License You apply must not prevent recipients of the Adapted Material from complying with this Public License.

Section 4 -- Sui Generis Database Rights.

Where the Licensed Rights include Sui Generis Database Rights that apply to Your use of the Licensed Material:

a. for the avoidance of doubt, Section 2(a)(1) grants You the right to extract, reuse, reproduce, and Share all or a substantial portion of the contents of the database for NonCommercial purposes only;

b. if You include all or a substantial portion of the database contents in a database in which You have Sui Generis Database Rights, then the database in which You have Sui Generis Database Rights (but not its individual contents) is Adapted Material; and

c. You must comply with the conditions in Section 3(a) if You Share all or a substantial portion of the contents of the database.

For the avoidance of doubt, this Section 4 supplements and does not replace Your obligations under this Public License where the Licensed Rights include other Copyright and Similar Rights.

Section 5 -- Disclaimer of Warranties and Limitation of Liability.

a. UNLESS OTHERWISE SEPARATELY UNDERTAKEN BY THE LICENSOR, TO THE EXTENT POSSIBLE, THE LICENSOR OFFERS THE LICENSED MATERIAL AS-IS AND AS-AVAILABLE, AND MAKES NO REPRESENTATIONS OR WARRANTIES OF ANY KIND CONCERNING THE LICENSED MATERIAL, WHETHER EXPRESS, IMPLIED, STATUTORY, OR OTHER. THIS INCLUDES, WITHOUT LIMITATION, WARRANTIES OF TITLE, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT, ABSENCE OF LATENT OR OTHER DEFECTS, ACCURACY, OR THE PRESENCE OR ABSENCE OF ERRORS, WHETHER OR NOT KNOWN OR DISCOVERABLE. WHERE DISCLAIMERS OF WARRANTIES ARE NOT ALLOWED IN FULL OR IN PART, THIS DISCLAIMER MAY NOT APPLY TO YOU.

b. TO THE EXTENT POSSIBLE, IN NO EVENT WILL THE LICENSOR BE LIABLE TO YOU ON ANY LEGAL THEORY (INCLUDING, WITHOUT LIMITATION, NEGLIGENCE) OR OTHERWISE FOR ANY DIRECT, SPECIAL, INDIRECT, INCIDENTAL, CONSEQUENTIAL, PUNITIVE, EXEMPLARY, OR OTHER LOSSES, COSTS, EXPENSES, OR DAMAGES ARISING OUT OF THIS PUBLIC LICENSE OR USE OF THE LICENSED MATERIAL, EVEN IF THE LICENSOR HAS BEEN ADVISED OF THE POSSIBILITY OF SUCH LOSSES, COSTS, EXPENSES, OR DAMAGES. WHERE A LIMITATION OF LIABILITY IS NOT ALLOWED IN FULL OR IN PART, THIS LIMITATION MAY NOT APPLY TO YOU.

c. The disclaimer of warranties and limitation of liability provided above shall be interpreted in a manner that, to the extent possible, most closely approximates an absolute disclaimer and waiver of all liability.

Section 6 -- Term and Termination.

a. This Public License applies for the term of the Copyright and Similar Rights licensed here. However, if You fail to comply with this Public License, then Your rights under this Public License terminate automatically.

b. Where Your right to use the Licensed Material has terminated under Section 6(a), it reinstates:

1. automatically as of the date the violation is cured, provided it is cured within 30 days of Your discovery of the violation; or

2. upon express reinstatement by the Licensor.

For the avoidance of doubt, this Section 6(b) does not affect any right the Licensor may have to seek remedies for Your violations of this Public License.

c. For the avoidance of doubt, the Licensor may also offer the Licensed Material under separate terms or conditions or stop distributing the Licensed Material at any time; however, doing so will not terminate this Public License.

d. Sections 1, 5, 6, 7, and 8 survive termination of this Public License.

Section 7 -- Other Terms and Conditions.

a. The Licensor shall not be bound by any additional or different terms or conditions communicated by You unless expressly agreed.

b. Any arrangements, understandings, or agreements regarding the Licensed Material not stated herein are separate from and independent of the terms and conditions of this Public License.

Section 8 -- Interpretation.

a. For the avoidance of doubt, this Public License does not, and shall not be interpreted to, reduce, limit, restrict, or impose conditions on any use of the Licensed Material that could lawfully be made without permission under this Public License.

b. To the extent possible, if any provision of this Public License is deemed unenforceable, it shall be automatically reformed to the minimum extent necessary to make it enforceable. If the provision cannot be reformed, it shall be severed from this Public License without affecting the enforceability of the remaining terms and conditions.

c. No term or condition of this Public License will be waived and no failure to comply consented to unless expressly agreed to by the Licensor.

d. Nothing in this Public License constitutes or may be interpreted as a limitation upon, or waiver of, any privileges and immunities that apply to the Licensor or You, including from the legal processes of any jurisdiction or authority.


Creative Commons is not a party to its public licenses. Notwithstanding, Creative Commons may elect to apply one of its public licenses to material it publishes and in those instances will be considered the “Licensor.” The text of the Creative Commons public licenses is dedicated to the public domain under the CC0 Public Domain Dedication. Except for the limited purpose of indicating that material is shared under a Creative Commons public license or as otherwise permitted by the Creative Commons policies published at creativecommons.org/policies, Creative Commons does not authorize the use of the trademark "Creative Commons" or any other trademark or logo of Creative Commons without its prior written consent including, without limitation, in connection with any unauthorized modifications to any of its public licenses or any other arrangements, understandings, or agreements concerning use of licensed material. For the avoidance of doubt, this paragraph does not form part of the public licenses.

Creative Commons may be contacted at creativecommons.org.